How Much Longer Will This Company Fly Under The Radar?
It looks like the market activity for GTBP is starting to really pick up and this could be a clear indicator that biotech investors are beginning to take notice! This up-and-coming biotech company has a therapy pipeline that has attracted some of the industry’s most experienced leaders. Now it looks like other outlets have started to look to GTBP for new market potential.
Alder Biopharmaceuticals, Inc. Appoints Jeremy Green to its Board of Directors
Alder Biopharmaceuticals, Inc., a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that its Board of Directors has unanimously appointed Jeremy Green, Founder and Portfolio Manager of Redmile Group, LLC (“Redmile”), to the Company’s Board, effective April 25, 2018. Mr. Green will serve as a Class III director with a term expiring at the Company’s 2020 Annual Meeting, filling a vacancy on the Board.
Disclaimer: Biotechstocks.com is owned by – MIDAM VENTURES LLC., a Florida Corporation that has been compensated $1,800,000.00 by a GT Biopharma Inc. for a period beginning August 1, 2017 and ending April. 30, 2018 to publicly disseminate information about (GTBP). We own zero shares. Biotechstocks.com is owned by – MIDAM VENTURES LLC., a Florida Corporation that has been compensated $200,000.00 by a GT Biopharma Inc. for a period beginning May 1, 2018 and ending May. 31, 2018 to publicly disseminate information about (GTBP). We own zero shares. Full Disclaimer Here